CASIF (CASI Pharmaceuticals) Cyclically Adjusted Book per Share: $4.79 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASIF CASI Pharmaceuticals Inc CASIF
29 GF Score
Price $0.13
GF Value $1.10
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Cyclically Adjusted Book per Share?

CASI Pharmaceuticals CASIF 29 Cyclically Adjusted Book per Share is $4.79 as of Dec. 2025. GuruFocus rates CASIF with a GF Score™ of 29/100 and a GF Value™ of $1.10 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CASI Pharmaceuticals's adjusted book value per share for the three months ended in Dec. 2025 was $-1.814. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.79 for the trailing ten years ended in Dec. 2025.

During the past 12 months, CASI Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 1.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -4.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of CASI Pharmaceuticals was 35.50% per year. The lowest was -53.60% per year. And the median was -18.60% per year.

As of today (2026-08-01), CASI Pharmaceuticals's current stock price is $0.1288. CASI Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was $4.79. CASI Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.03.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of CASI Pharmaceuticals was 10.56. The lowest was 0.02. And the median was 1.25.


CASI Pharmaceuticals  (OTCPK:CASIF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CASI Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.1288/4.79
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of CASI Pharmaceuticals was 10.56. The lowest was 0.02. And the median was 1.25.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CASI Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


CASI Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Cyclically Adjusted Book per Share Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.23 5.45 4.96 4.74 4.79

CASI Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.74 4.75 4.74 4.77 4.79

CASIF vs DCOY, PKTX, BIXT: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


CASIF
29GF Score
CASI Pharmaceuticals Inc CASIF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CASI Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-1.814/115.8323*115.8323
=-1.814

Current CPI (Dec. 2025) = 115.8323.

CASI Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201603 1.089 102.200 1.234
201606 2.111 101.400 2.411
201609 3.240 102.400 3.665
201612 3.452 102.600 3.897
201703 3.196 103.200 3.587
201706 2.828 103.100 3.177
201709 2.588 104.100 2.880
201712 5.520 104.500 6.119
201803 8.491 105.300 9.340
201806 9.655 104.900 10.661
201809 12.133 106.600 13.184
201812 11.487 106.500 12.494
201903 10.885 107.700 11.707
201906 9.302 107.700 10.004
201909 8.342 109.800 8.800
201912 7.466 111.200 7.777
202003 6.973 112.300 7.192
202006 6.276 110.400 6.585
202009 7.385 111.700 7.658
202012 6.579 111.500 6.835
202103 7.155 112.662 7.356
202106 6.781 111.769 7.028
202109 6.195 112.215 6.395
202112 6.044 113.108 6.190
202203 5.511 114.335 5.583
202206 4.920 114.558 4.975
202209 4.536 115.339 4.555
202212 3.312 115.116 3.333
202303 2.971 115.116 2.989
202306 2.419 114.558 2.446
202309 2.152 115.339 2.161
202312 1.806 114.781 1.823
202403 1.154 115.227 1.160
202406 0.625 114.781 0.631
202409 0.896 115.785 0.896
202412 0.119 114.893 0.120
202503 -0.521 115.116 -0.524
202506 -1.311 114.907 -1.322
202509 -1.391 115.471 -1.395
202512 -1.814 115.832 -1.814

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $4.79 mean?
CASI Pharmaceuticals (CASIF) has a Cyclically Adjusted Book per Share of $4.79 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Cyclically Adjusted Book per Share too high?
CASI Pharmaceuticals' current Cyclically Adjusted Book per Share is $4.79. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Cyclically Adjusted Book per Share compare to DCOY and PKTX?
CASI Pharmaceuticals' Cyclically Adjusted Book per Share of $4.79 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Cyclically Adjusted Book per Share is $4.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.10, compared to a current price of $0.13 — trading 88.3% below its estimated fair value. The current Cyclically Adjusted Book per Share is $4.79. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current Cyclically Adjusted Book per Share is $4.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of $0.13 is trading 88.3% below its estimated GF Value™ of $1.10. GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CASIF:

  • Cyclically Adjusted Book per Share: $4.79
  • GF Value™: $1.10 vs. price of $0.13 (88.3% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CASI Pharmaceuticals Business Description

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for CASIF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$1.10
GF Value